AllGen Financial Advisors Inc. Acquires 59 Shares of Becton, Dickinson and Company (NYSE:BDX)

AllGen Financial Advisors Inc. lifted its holdings in Becton, Dickinson and Company (NYSE:BDX) by 0.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,698 shares of the medical instruments supplier’s stock after purchasing an additional 59 shares during the quarter. Becton, Dickinson and Company accounts for about 1.1% of AllGen Financial Advisors Inc.’s investment portfolio, making the stock its 23rd biggest holding. AllGen Financial Advisors Inc.’s holdings in Becton, Dickinson and Company were worth $2,121,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the business. Vanguard Group Inc. lifted its stake in Becton, Dickinson and Company by 2.0% during the 3rd quarter. Vanguard Group Inc. now owns 25,927,519 shares of the medical instruments supplier’s stock valued at $6,703,041,000 after acquiring an additional 516,427 shares during the period. Morgan Stanley boosted its holdings in Becton, Dickinson and Company by 4.5% in the third quarter. Morgan Stanley now owns 10,200,213 shares of the medical instruments supplier’s stock worth $2,637,062,000 after purchasing an additional 435,168 shares during the last quarter. Massachusetts Financial Services Co. MA raised its stake in Becton, Dickinson and Company by 11.0% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 5,192,832 shares of the medical instruments supplier’s stock valued at $1,342,503,000 after buying an additional 512,566 shares during the last quarter. Ameriprise Financial Inc. lifted its holdings in shares of Becton, Dickinson and Company by 9.2% during the 3rd quarter. Ameriprise Financial Inc. now owns 3,630,351 shares of the medical instruments supplier’s stock valued at $938,593,000 after buying an additional 304,629 shares during the period. Finally, Clearbridge Investments LLC boosted its stake in shares of Becton, Dickinson and Company by 2.9% in the 3rd quarter. Clearbridge Investments LLC now owns 3,135,238 shares of the medical instruments supplier’s stock worth $810,553,000 after buying an additional 89,714 shares during the last quarter. 86.97% of the stock is owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Stock Performance

Becton, Dickinson and Company stock traded down $5.67 during trading on Friday, reaching $234.68. The company had a trading volume of 1,722,353 shares, compared to its average volume of 1,291,373. The firm has a market capitalization of $67.80 billion, a price-to-earnings ratio of 51.69, a price-to-earnings-growth ratio of 1.93 and a beta of 0.45. The company has a current ratio of 1.41, a quick ratio of 0.64 and a debt-to-equity ratio of 0.62. The firm’s 50-day simple moving average is $238.45 and its 200 day simple moving average is $240.27. Becton, Dickinson and Company has a 52 week low of $229.40 and a 52 week high of $287.32.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, May 2nd. The medical instruments supplier reported $3.17 EPS for the quarter, topping the consensus estimate of $2.97 by $0.20. The firm had revenue of $5.05 billion for the quarter, compared to the consensus estimate of $5.04 billion. Becton, Dickinson and Company had a return on equity of 13.90% and a net margin of 6.76%. The business’s revenue for the quarter was up 4.6% compared to the same quarter last year. During the same quarter last year, the company earned $2.86 earnings per share. Sell-side analysts forecast that Becton, Dickinson and Company will post 13.04 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 28th. Shareholders of record on Monday, June 10th will be given a $0.95 dividend. The ex-dividend date is Monday, June 10th. This represents a $3.80 dividend on an annualized basis and a dividend yield of 1.62%. Becton, Dickinson and Company’s payout ratio is currently 83.70%.

Insider Buying and Selling

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,715 shares of the firm’s stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $232.81, for a total transaction of $399,269.15. Following the sale, the executive vice president now directly owns 5,381 shares of the company’s stock, valued at $1,252,750.61. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 282 shares of the stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $238.29, for a total transaction of $67,197.78. Following the completion of the transaction, the senior vice president now owns 2,276 shares of the company’s stock, valued at approximately $542,348.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Michael David Garrison sold 1,715 shares of the firm’s stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total value of $399,269.15. Following the transaction, the executive vice president now owns 5,381 shares of the company’s stock, valued at approximately $1,252,750.61. The disclosure for this sale can be found here. 0.31% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Separately, Barclays upped their price objective on Becton, Dickinson and Company from $301.00 to $305.00 and gave the company an “overweight” rating in a research report on Monday, February 5th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, Becton, Dickinson and Company has an average rating of “Moderate Buy” and a consensus target price of $280.00.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.